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Tendon repair is a challenging procedure in orthopaedics. The use of mesenchymal stem cells (MSCs) and pulsed electromagnetic
ﬁelds (PEMF) in tendon regeneration is still investigational. In this perspective, MSCs isolated from the human umbilical cord (UC)
may represent a possible candidate for tendon tissue engineering. The aim of the study is to evaluate the eﬀect of low-frequency
PEMF on tenogenic diﬀerentiation of MSCs isolated from the human umbilical cord (UC-MSCs) in vitro. 15 fresh UC samples
from women with healthy pregnancies were retrieved at the end of caesarean deliveries. UC samples were manually minced into
small fragments (less than 4mm length) and cultured in MSC expansion medium. Part of the UC-MSCs was subsequently
cultured with PEMF and tenogenic growth factors. UC-MSCs were subjected to pulsed electromagnetic ﬁelds for 2 h/day,
4 h/day, or 8 h/day. UC-MSCs cultured with FGF-2 and stimulated with PEMF showed a greater production of collagen type I
and scleraxis. The prolonged exposure to PEMF was also related to the greatest expression of tenogenic markers. Thus, the
exposure to PEMF provides a positive preconditioning biophysical stimulus, which may enhance UC-MSC tenogenic potential.
1. Introduction
Tendon repair and regeneration are still an unsolved prob-
lem in orthopaedics. Indeed, the tendon healing may be
subjected to failure, due to the incomplete restoration of
the tendon body and to the lack of osteointegration at
the level of the enthesis. As an example, rerupture of the
Achilles tendon is frequent with a rate of approximately 5%
in the surgically treated cases and up to 12% in the case of
conservative treatment [1]. Moreover, surgical reconstructive
procedures may obtain good repair of the tendon to the ana-
tomic insertion site, but the integration at the enthesis is
often unsuccessful, leading to the formation of a ﬁbrotic scar.
Thus, the rerupture rate after rotator cuﬀ repair is approxi-
mately 25% of cases and even more in the occurrence of large
cuﬀ tears, as shown in literature [2–4]. Thus, an enhance-
ment of the tenogenic process during tendon regeneration
and an improvement of the enthesis reconstruction may
ameliorate the ﬁnal results of tendon repair.
Diﬀerent studies have focused on the key elements of ten-
don regeneration; in particular, cell preconditioning toward
the tenogenic line may represent a possible solution to
improve tendon regeneration. Several attempts have been
made to increase enthesis and tendon regeneration by adding
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undiﬀerentiated MSCs with unsatisfying results, as shown by
the recent works of Gulotta et al. [5] and Kraus et al. [6].
Conversely, scleraxis gene transduction leads to a satisfactory
result in preclinical mouse models of rotator cuﬀ repair [7].
In addition to transgenic techniques, physical forces may
exert a positive eﬀect on the cell microenvironment, as
observed with extracorporeal shock wave and pulsed electro-
magnetic ﬁelds (PEMF) [8–11]. Thus, a “microenvironmen-
tal eﬀect” by biophysical forces may represent an alternative
key element to obtain MSC preconditioning toward the
tenogenic pathway.
Indeed, PEMF exposure [12, 13] on human tendon deter-
mined increased scleraxis and collagen type I expression, as
well as increased production of IL-10 and VEGF, also
involved in the tendon healing process. These results may
suggest a possible “biologic scenario” to improve MSC teno-
genic development with the application of PEMF. In this
work, we analyzed UC-MCS exposed to PEMF and FGF-2,
to investigate the possible role of PEMF exposure in teno-
genic diﬀerentiation. In a possible future clinical context,
the use of an allogeneic source of MSCs is an attractive
approach with several advantages, such as the unlimited
availability of cells and the absence of patient morbidity.
Indeed, the potential wide availability of the umbilical cord
after caesarean births allows for the isolation of a consider-
able number of cells hypothetically available for storage in
stem cell factories. Thus, in this perspective, UC-MSCs may
be conceived as an “oﬀ-the-shelf” ready-to-use cell source
to be used for diﬀerent orthopaedic reconstructive proce-
dures such as tendon repair. Moreover, the umbilical cord
may be deﬁned as a “waste material” with intrinsic low ethi-
cal concerns for future clinical applications. A promising dif-
ferentiation potential of UC-MSCs toward mesenchymal cell
lines has been recently demonstrated in previous in vitro
studies [14–16].
2. Materials and Methods
Approvals were obtained both from the Ethical Committee
of MBC (Molecular Biotechnology Center), University of
Turin, and from the Ethical Committee of Mauriziano
Hospital, Turin (Italy) (protocol number: CS792, approved
on January 11, 2016).
2.1. UC Collection and Processing. After obtaining a speciﬁc
patient’s informed consent, fresh UC samples from 15
women with healthy pregnancies were recovered during cae-
sarean deliveries from the Department of Obstetrics and
Gynecology of Mauriziano Hospital (Turin, Italy). UC sam-
ples were collected into phosphate-buﬀered saline (PBS)
(Invitrogen, Carlsbad, CA, USA) transfer medium contain-
ing 200mg/100mL ciproﬂoxacin (Bayer, Milan, Italy) and
500 IU heparin (Pharmatex, Milan, Italy). Then, cord length
and weight were assessed. UC segments were then manually
minced into small cuboidal fragments (4–7mm length).
The umbilical cord fragments were seeded in 60 cm2 Petri
dishes and cultured in expansion medium containing Dul-
becco’s modiﬁed Eagle medium/F-12 (D-MEM) (Invitrogen,
Carlsbad, CA, USA), 5% human platelet lysate obtained from
healthy donors, 10% fetal bovine serum (FBS), 1X penicillin/
streptomycin (Invitrogen, Carlsbad, CA, USA), 1X sodium
pyruvate (Invitrogen, Carlsbad, CA, USA), 1X nonessential
amino acids (Invitrogen, Carlsbad, CA, USA), and 500 IU
heparin (Pharmatex, Milan, Italy).
UC fragments were distributed into diﬀerent 60 cm2 Petri
dishes (approximately 40–45 fragments/Petri dish) and incu-
bated in the MSC expansion medium at 37°C in a humidiﬁed
atmosphere with 5% CO2 for up to 2 weeks.
2.2. Culture andUC-MSC Immunophenotypic Characterization.
Subsequently, UC debris were removed and adherent cells
were expanded for 2 additional weeks.
40% of the medium was changed every 3-4 days. Adher-
ent cells (P0) were then trypsinized, centrifuged, resuspended
in MSC expansion medium, and replated for one consecutive
expansion step at a density of 100–200 cells/cm2, until full
conﬂuence was reached (P1). Cell conﬂuence at P1 was
reached after approximately 14 days (day 42).
At the end of P1, living cells were counted by trypan
blue dye.
Immunophenotyping of the expanded UC-MSCs was
performed by ﬂow cytometry analysis at P1. The following
antibodies were used: CD90-peridinin chlorophyll protein-
(PerCP) cyanine dye Cy5.5 (BioLegend, San Diego, CA),
CD105-ﬂuorescein isothiocyanate (FITC) (BioLegend, San
Diego, CA), CD73-allophycocyanin (APC) (BD Biosciences,
San Jose, CA), CD34-phycoerythrin (PE) (BD Biosciences,
San Jose, CA), HLA-DR-FITC (BD Biosciences, San Jose,
CA), HLA-PerCP (BD Biosciences, San Jose, CA), HLA-
ABC-PE, CD29-APC (BD Biosciences, San Jose, CA),
CD44-Alexa Fluor (Cell Signaling Technology, Danvers,
MA), PE-conjugated anti-mouse immunoglobulin G (IgG)
(Southern Biotechnology Associates, Birmingham, Alabama,
USA), isotype-matched IgG-FITC (BioLegend, San Diego,
CA), IgG-PE (BioLegend, San Diego, CA), and IgG-PE-Cy5
(BioLegend, San Diego, CA) control antibodies. Analysis
was performed on a FACScan (Becton Dickinson (BD),
Buccinasco, Italy) for at least 10,000 events using CellQuest
software (BD, Buccinasco, Italy).
2.3. UC-MSC Tendon Diﬀerentiation. UC-MSCs were
plated at a density of 5× 103 cells/cm2. The diﬀerentiation
medium was composed of DMEM (Invitrogen, Carlsbad,
CA, USA), 10% fetal calf serum, 50U/mL penicillin (Invitro-
gen, Carlsbad, CA, USA), 50 lg/mL streptomycin (Invitrogen,
Carlsbad, CA, USA), 2mM L-glutamine (Invitrogen, Carls-
bad, CA, USA), and 5ng/mL basic ﬁbroblast growth factor
(b-FGF-2) (PeproTech, Rocky Hill, New Jersey). UC-MSCs
were cultured in tendon diﬀerentiation medium for 7, 14,
and 21 days. The following experimental and control groups
were analyzed:
(i) UC-MSCs cultured in the diﬀerentiation medium
and exposed to PEMF for 2 hours (PEMF1 group),
4 hours (PEMF2 group), or 8 hours (PEMF3 group)
(ii) UC-MSCs cultured in the diﬀerentiation medium
without exposure to PEMF (CTRL1)
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(iii) UC-MSCs cultured in control medium (DMEM
+10% fetal calf serum, 50U/mL penicillin/strepto-
mycin, and 2mM L-glutamine) and not exposed to
PEMF (CTRL2)
Cultured cells were analyzed at day 0, day 7, day 14, and
day 21.
PEMF stimulation was carried out as previously
described by de Girolamo et al. [12]. UC-MSCs were exposed
to PEMF generated by a pair of rectangular horizontal coils
placed at opposite sites and composed of 1000 turns of cop-
per wire. The culture plate was placed between the coils,
keeping the plane of the coils parallel to the culture ﬂasks.
The coils were linked to a PEMF generator system (IGEA,
Carpi, Italy) as previously described in several works [12,
13]. The system was able to produce a pulsed signal with a
duration of 1.3ms and a frequency of 75Hz (yielding a 0.1
duty cycle). This corresponded to a peak intensity of the
magnetic ﬁeld of 1.5mT.
2.4. Cell Apoptosis Analysis with Annexin V/Propidium
Iodide. Apoptosis was analyzed at 7, 14, and 21 days of diﬀer-
entiation with annexin V FITC/propidium iodide (PI) stain-
ing (Thermo Fisher Scientiﬁc, Waltham, Massachusetts,
USA). Apoptosis was expressed as a percentage of positive
cells (annexin V+/PI− and annexin V+/PI+).
2.5. Immunoﬂuorescence Analysis. Expression of the tenocyte
markers scleraxis (Santa Cruz Biotechnology, Dallas, Texas,
USA), collagen type I (Merck Millipore, Milano, Italy) and
the proliferative marker PCNA (Santa Cruz Biotechnology,
Dallas, Texas, USA) was assessed by immunoﬂuorescence.
Primary monoclonal antibodies were diluted at 1 : 200 in
PBS-1% BSA and incubated with the sections for 2 h at room
temperature. The secondary DyLight 488 antibody (KPL,
Kirkegaard & Perry Laboratories, Maryland, USA), diluted
at 1 : 100, was incubated for 1 h at room temperature. Stained
sections were visualized with an Apotome ﬂuorescence
microscope (Zeiss). We collected digital images using a ×20
dry lens within 0–5 days after labeling.
2.6. Evaluation of Fluorescence Intensity. We have evaluated
the diﬀerence of ﬂuorescence intensity between groups using
the ImageJ program. This software generated numerical
semiquantitative evaluations corresponding to the mean of
ﬂuorescence intensity of each image examined. Ten cellular
ﬁelds were randomly chosen among the diﬀerent areas of
migrated cells in each slide. Brieﬂy, a point tool enables
to mark diﬀerent points on each image. With each “click,”
the coordinates of the mark (xx, yy) and brightness values
(0–255) are recorded in the data window. ImageJ brightness
units are in a scale where 0 is pure black and 255 is pure
white. Brightness values for each image were calculated as
the arithmetical mean of all values in all ﬁelds recorded
for that image. For each group, the mean ﬂuorescence
intensity of each marker was calculated and plotted in a
graph. The diﬀerence in signal intensity allowed for evalu-
ating the change in marker expression between the diﬀerent
culture conditions.
2.7. IL-10 and VEGF-A ELISA Analysis. IL-10 and VEGF-A
expression in the culture medium was analyzed at 7, 14,
and 21 days with a commercially available ELISA test, follow-
ing the manufacturer’s protocols (R&D Systems, Minneapo-
lis, MN, USA).
2.8. Statistical Analysis. All data in the text and ﬁgures are
provided as means± standard deviation (SD). To compare
the three diﬀerent conditions, we have adopted the one-way
ANOVA and Bonferroni adjustment. Statistical analysis
was carried out with the statistical software package Graph-
Pad Prism 5.0 (GraphPad Software).
3. Results (See Supplemental Results
(Available Here))
3.1. UC-MSC Morphologic and Immunophenotypic
Characterization. In primary cultures, typical spindle-
shaped adherent cells were observed migrating from the
UC tissue fragments and starting the colony formation
approximately at day 14 after seeding. The UC immunophe-
notype was analyzed by ﬂow cytometry. The majority of the
collected UC cells showed positive expression of the main
MSC markers CD73, CD90, and CD105, as well as of CD44
and CD29. Furthermore, they were negative for the typical
hematopoietic marker CD34. The data also demonstrated
the presence of HLA-ABC proteins and the absence of
HLA-DR (data not shown).
3.2. Immunoﬂuorescence Analysis. Immunoﬂuorescence
analysis revealed scleraxis, collagen type I (Col I), and prolif-
erating cell nuclear antigen (PCNA) expression.
3.2.1. Scleraxis. At day 7 (Figure 1), a greater presence of
scleraxis-positive cells was observed in PEMF2 and PEMF3
groups. Moreover, there was a progressive increase in the
absolute values of intensity of ﬂuorescence with a prolonged
exposure to PEMF (Figures 1(a)–1(c)).
At day 14 (Figure 2), we obtained similar results
(Figures 2(a)–2(c)).
At day 21, there was a signiﬁcant increase in the intensity
of ﬂuorescence in the experimental groups exposed to PEMF
(Figure 3), especially in the PEMF3 group.
3.2.2. Type I Collagen. From day 7, samples exposed to PEMF
showed signiﬁcantly higher ﬂuorescence intensity values
than the two control conditions, with signiﬁcant diﬀerences
in PEMF2 and PEMF3 groups. The addition of the tenogenic
growth factor FGF-2 to the culture medium determined
greater expression of type I collagen (Figures 4(a)–4(c)).
At day 14 (Figure 5), cells exposed to PEMF expressed
signiﬁcantly greater amounts of type I collagen. There was
also a gradual increase in the absolute values of ﬂuorescence
intensity with time.
At the end of the three weeks (day 21) (Figure 6), ﬂuores-
cence intensity was signiﬁcantly greater in the 3 experimental
groups exposed to PEMF. The 8-hour exposure protocol met
the signiﬁcance criteria with a p value < 0.0001 compared
to the control groups. Moreover, FGF-2 did not aﬀect type
I collagen expression (Figures 6(a)–6(c)).
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3.2.3. PCNA. After a week (day 7) of PEMF exposure, PCNA
expression was not signiﬁcantly higher than the PCNA
expression in CTRL1, except for PCNA expression in the 4-
hour protocol (Figure 7). Moreover, PEMF exposure or the
presence of FGF-2 did not negatively aﬀect PCNA expression
(Figures 7(a)–7(c)).
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Figure 1: Scleraxis expression after 7 days of cell culture. (a) Immunoﬂuorescent analysis for scleraxis expression and quantiﬁcation of
ﬂuorescence intensity in UC-MSC cultures with and without PEMF exposure for 2 hours/day. (b) Immunoﬂuorescent analysis for
scleraxis expression and quantiﬁcation of ﬂuorescence intensity in UC-MSC cultures with and without PEMF exposure for 4 hours/day.
(c) Immunoﬂuorescent analysis for scleraxis expression and quantiﬁcation of ﬂuorescence intensity in UC-MSC cultures with and without
PEMF exposure for 8 hours/day. ∗∗∗Indicates the p-vaule (probability value, statistical signiﬁcance level <0 05) between two speciﬁc
groups of study, ns: indicates a non signiﬁcant value.
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Figure 2: Scleraxis expression after 14 days of cell culture. (a) Immunoﬂuorescent analysis for scleraxis expression and quantiﬁcation of
ﬂuorescence intensity in UC-MSC cultures with and without PEMF exposure for 2 hours/day. (b) Immunoﬂuorescent analysis for
scleraxis expression and quantiﬁcation of ﬂuorescence intensity in UC-MSC cultures with and without PEMF exposure for 4 hours/day.
(c) Immunoﬂuorescent analysis for scleraxis expression and quantiﬁcation of ﬂuorescence intensity in UC-MSC cultures with and without
PEMF exposure for 8 hours/day. ∗∗∗Indicates the p-value (probability value, statistical signiﬁcance level <0 05) between two speciﬁc
groups of study, ns: indicates a non signiﬁcant value.
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Figure 3: Scleraxis expression after 21 days of cell culture. (a) Immunoﬂuorescent analysis for scleraxis expression and quantiﬁcation of
ﬂuorescence intensity in UC-MSC cultures with and without PEMF exposure for 2 hours/day. (b) Immunoﬂuorescent analysis for
scleraxis expression and quantiﬁcation of ﬂuorescence intensity in UC-MSC cultures with and without PEMF exposure for 4 hours/day.
(c) Immunoﬂuorescent analysis for scleraxis expression and quantiﬁcation of ﬂuorescence intensity in UC-MSC cultures with and without
PEMF exposure for 8 hours/day. ∗∗∗Indicates the p-value (probability value, statistical signiﬁcance level <0 05) between two speciﬁc
groups of study.
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At day 14, we observed a signiﬁcantly greater ﬂuores-
cence signal in CTRL1 than in the PEMF1 experimental
group (Figure 8). There was no signiﬁcant diﬀerence between
PEMF3 and CTRL1 groups (Figures 8(a)–8(c)).
At the end of the three weeks (day 21), PCNA
expression was lower in PEMF groups (especially
PEMF2 and PEMF3) than in the CTRL1 group
(Figures 9(a)–9(c)).
3.3. IL-10 and VEGF Analysis. The immunoenzymatic test
provided data on the presence of two major cytokines with
modulating action on the immune and inﬂammatory
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Figure 4: Type I collagen expression after 7 days of cell culture. (a) Immunoﬂuorescent analysis for type I collagen expression and
quantiﬁcation of ﬂuorescence intensity in UC-MSC cultures with and without PEMF exposure for 2 hours/day. (b) Immunoﬂuorescent
analysis for type I collagen expression and quantiﬁcation of ﬂuorescence intensity in UC-MSC cultures with and without PEMF exposure
for 4 hours/day. (c) Immunoﬂuorescent analysis for type I collagen expression and quantiﬁcation of ﬂuorescence intensity in UC-MSC
cultures with and without PEMF exposure for 8 hours/day. ∗∗∗Indicates the p-value (probability value, statistical signiﬁcance level <0 05)
between two speciﬁc groups of study, ns: indicates a non signiﬁcant value.
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Figure 5: Type I collagen expression after 14 days of cell culture. (a) Immunoﬂuorescent analysis for type I collagen expression
and quantiﬁcation of ﬂuorescence intensity in UC-MSC cultures with and without PEMF exposure for 2 hours/day. (b)
Immunoﬂuorescent analysis for type I collagen expression and quantiﬁcation of ﬂuorescence intensity in UC-MSC cultures
with and without PEMF exposure for 4 hours/day. (c) Immunoﬂuorescent analysis for type I collagen expression and
quantiﬁcation of ﬂuorescence intensity in UC-MSC cultures with and without PEMF exposure for 8 hours/day. ∗∗∗Indicates
the p-value (probability value, statistical signiﬁcance level <0 05) between two speciﬁc groups of study, ns: indicates a non
signiﬁcant value.
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response: interleukin-10 (IL-10) and vascular endothelial
growth factor (VEGF).
Analysis of IL-10 production revealed a linear growth in
PEMF2 and PEMF3 groups (Figure 10(a)). The curve slope
increased with the progressive increase in PEMF exposure,
with value shift between days 7, 14, and 21. Figure 10(b)
showed a remarkable increase in VEGF values starting from
day 14 in the PEMF3 group.
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Figure 6: Type I collagen expression after 21 days of cell culture. (a) Immunoﬂuorescent analysis for type I collagen expression and
quantiﬁcation of ﬂuorescence intensity in UC-MSC cultures with and without PEMF exposure for 2 hours/day. (b) Immunoﬂuorescent
analysis for type I collagen expression and quantiﬁcation of ﬂuorescence intensity in UC-MSC cultures with and without PEMF exposure
for 4 hours/day. (c) Immunoﬂuorescent analysis for type I collagen expression and quantiﬁcation of ﬂuorescence intensity in UC-MSC
cultures with and without PEMF exposure for 8 hours/day. ∗∗∗Indicates the p-value (probability value, statistical signiﬁcance level <0 05)
between two speciﬁc groups of study, ns: indicates a non signiﬁcant value.
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Comparing the diﬀerent culture conditions (exposed to
PEMF and not exposed to PEMF), we did not notice at 7 days
any signiﬁcant diﬀerences in IL-10 expression between
PEMF-exposed groups and control groups (Figure 11). In
the CTRL2 group (without PEMF and FGF), there were sta-
ble values of IL-10 from day 7 to day 14, followed by a fall at
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Figure 7: PCNA expression after 7 days of cell culture. (a) Immunoﬂuorescent analysis for PCNA expression and quantiﬁcation of
ﬂuorescence intensity in UC-MSC cultures with and without PEMF exposure for 2 hours/day. (b) Immunoﬂuorescent analysis for PCNA
expression and quantiﬁcation of ﬂuorescence intensity in UC-MSC cultures with and without PEMF exposure for 4 hours/day. (c)
Immunoﬂuorescent analysis for PCNA expression and quantiﬁcation of ﬂuorescence intensity in UC-MSC cultures with and without
PEMF exposure for 8 hours/day. ∗∗∗Indicates the p-value (probability value, statistical signiﬁcance level <0 05) between two speciﬁc
groups of study.
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day 21. In the CTRL1 group (with FGF but without PEMF),
stationary concentrations were found at all culture time
points (i.e., at 7, 14, and 21 days). On the other hand, in the
PEMF-exposed cultures (i.e., UC-MSC cultures with PEMF
and FGF), a signiﬁcant increased release of IL-10 was
observed with the conditions of 4 and 8 hours per day of
PEMF exposure (PEMF2 and PEMF3 groups) at day 14
and, more markedly, at day 21.
VEGF expression was higher in all PEMF-exposed cul-
tures (PEMF1, PEMF2, and PEMF3) than in control groups.
In the control group exposed to FGF-2 (CTRL1 group), the
presence of FGF positively inﬂuenced VEGF expression with
time, with values inferior to those observed in the PEMF-
exposed groups. The largest deviation in VEGF production
between PEMF-exposed cultures and control cultures not
exposed to PEMF (CTRL1 and CTRL2 groups) was observed
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Figure 8: PCNA expression after 14 days of cell culture. (a) Immunoﬂuorescent analysis for PCNA expression and quantiﬁcation of
ﬂuorescence intensity in UC-MSC cultures with and without PEMF exposure for 2 hours/day. (b) Immunoﬂuorescent analysis for PCNA
expression and quantiﬁcation of ﬂuorescence intensity in UC-MSC cultures with and without PEMF exposure for 4 hours/day. (c)
Immunoﬂuorescent analysis for PCNA expression and quantiﬁcation of ﬂuorescence intensity in UC-MSC cultures with and without
PEMF exposure for 8 hours/day. ∗∗∗Indicates the p-value (probability value, statistical signiﬁcance level <0 05) between two speciﬁc
groups of study.
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to be related to the group exposed to PEMF for 8 hours daily
(PEMF3) (Figure 11(f)).
3.4. Cell Viability Analysis. Cell mortality data at day 7
showed 95.23% survival rate for PEMF1, 80.83% for
PEMF2, and 90.17% for PEMF3, with the highest per-
centage of necrosis and apoptosis (PI-positive cells or PI-
and annexin-positive cells) found in the PEMF2 group
(Figure 12).
At day 14, there was a decrease in the percentage of sur-
viving cells in all the three experimental groups, particularly
in PEMF3, in which, besides a decrease of about 17.5% of
the live cells, there was a percentage of 14.87% cells in early
apoptosis (Figures 12(d)–12(f)). The lowest percentage of
cell survival was reported in 4 h exposure protocol (65.86%)
with 25.79% positive double cells.
At the ﬁnal time point at three weeks (day 21), we
found a further decrease in cell survival in the 2- and 4-
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Figure 9: PCNA expression after 21 days of cell culture. (a) Immunoﬂuorescent analysis for PCNA expression and quantiﬁcation of
ﬂuorescence intensity in UC-MSC cultures with and without PEMF exposure for 2 hours/day. (b) Immunoﬂuorescent analysis for PCNA
expression and quantiﬁcation of ﬂuorescence intensity in UC-MSC cultures with and without PEMF exposure for 4 hours/day. (c)
Immunoﬂuorescent analysis for PCNA expression and quantiﬁcation of ﬂuorescence intensity in UC-MSC cultures with and without
PEMF exposure for 8 hours/day. ∗∗∗Indicates the p-value (probability value, statistical signiﬁcance level <0 05) between two speciﬁc
groups of study, ns: indicates a non signiﬁcant value.
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hour protocols (19% and 17%, resp.), consensually with the
negative trend already recorded in the previous analyses
(Figures 12(g)–12(i)). In the 8-hour culture, however, there
was a very high percentage of surviving cells (91.95%) com-
pared to that at day 14 (72.67%).
4. Discussion
The main ﬁnding of this study is that the exposure to PEMF
(of 1.5mT and 75Hz) provides a biophysical stimulus, which
signiﬁcantly enhances the in vitro tendon commitment of
human UC-MSCs. Thus, exposure to PEMF may represent
an alternative biologic scenario of MSC preconditioning
toward the tenogenic pathway.
Moreover, our study suggests that the combination of
PEMF and allogeneic human UC-MSCs may represent a pos-
sible therapeutic alternative for tendon tissue engineering.
These results, indeed, may have a clinical relevance for future
preclinical and clinical models of tendon regeneration and
rotator cuﬀ reconstructive surgery.
The role of MSCs in tendon repair and regeneration is
still a debated topic in literature. Several observations from
diﬀerent authors have questioned the possible positive inﬂu-
ence of the direct application of undiﬀerentiated MSCs at a
tendon lesion site. Gulotta et al. [5] have shown that the
use of bone marrow-derived MSCs in the repair of rotator
cuﬀ lesions in rats did not improve the healing potential, sug-
gesting that the simple enrichment with MSCs at the lesion
site was not suﬃcient for tissue regeneration. A similar obser-
vation was conﬁrmed by Okamoto et al. [17] who showed
better results with the bone marrow concentrate when com-
pared to a puriﬁed suspension of precultured undiﬀerenti-
ated MSCs in a healing model of Achilles tendon lesion in
rats. More recently, Huang et al. [18] observed improvements
in the healing of rat Achilles tendon rupture when MSCs
were preactivated in hypoxic conditions. This result suggests
the need for a supplemental signal for MSCs to be eﬃciently
“preconditioned” toward the tenogenic pathway and to pos-
itively interfere with the tendon and enthesis repair, as also
recently indicated by Chamberlain et al. [19]. Thus, this con-
cept may represent a possible answer to the putative “elu-
sive” role of MSCs in tendon [5]. Indeed, the hypoxic
culture represents an alternative method to activate MSCs,
leading them toward a speciﬁc chondrogenic pathway.
Moreover, the whole bone marrow may include some of
the “stem cell niche” that may produce biologic factors able
to activate in situ resident MSCs as well as the few MSCs
present in the bone marrow aspirate. Moving further, few
studies have demonstrated that also the gene transfer proce-
dure may be considered a solution for MSC preconditioning,
through the transfection of scleraxis [7] or membrane type 1
matrix metalloproteinase [20]. Very recently, the association
of the cortical allogeneic demineralized bone matrix and
MSCs has also given promising results in a rat model of
supraspinatus lesion. This is in line with the concept of
“MSC preconditioning,” due to the ability of demineralized
bone matrix to release growth factors (i.e., bone morphoge-
netic proteins) [21]. This study, nevertheless, introduces a
concept of “ﬁne tuning” eﬀect of MSCs on the microenvi-
ronment, in line with a diﬀerent in vitro study by Rehmann
et al. who demonstrated the increased production of teno-
genic proteins by MSCs in the presence of a speciﬁc bioac-
tive scaﬀold [22].
In summary, one of the key factors to promote MSC
tenogenic potential resides in the “preactivation” or “precon-
ditioning” of these progenitor cells, by direct intracellular
stimulation (i.e., gene transfection) or by exerting a positive
stimulus on the MSC microenvironment.
From this perspective, PEMF may represent a promising
and cost-eﬃcient alternative. Indeed, the positive role of
PEMF in the mesenchymal healing process is well known
in literature [10]. Several studies have shown that PEMF
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Figure 10: IL-10 and VEGF expression in UC-MSC cultures exposed to PEMF. (a) Analysis of IL-10 levels in cultures exposed to FGF-2 and
PEMF at diﬀerent PEMF expositions (2, 4, and 8 h/day) after 7, 14, and 21 days. (b) Analysis of VEGF levels in cultures exposed to FGF-2 and
PEMF at diﬀerent PEMF expositions (2, 4, and 8 h/day) after 7, 14, and 21 days.
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may activate several cellular mediators, such as adenosine
receptors [23], which are linked to the inhibition of the acti-
vation of transcription factor NF-κB. Furthermore, PEMF
seems to interact with the ligand-independent activation of
the epidermal growth factor receptor (EGFR) and other
members of the receptor tyrosine kinase family that are
involved in the activation of the MAPK (mitogen-activated
protein kinase)/ERK (extracellular signal-regulated kinase)
pathway and in the stimulation of the intracellular mitogenic
pathways [10, 24]. Wnt signaling proteins (Wnt1/lipoprotein
247 receptor-related protein 5 (LRP5)/beta-catenin) may
also be involved in the PEMF mechanism, outlining the
possible anabolic role of PEMF toward mesenchymal cell
proliferation. Further studies are needed to better clarify the
still “hidden” mechanisms activated by PEMF stimulation.
Nonetheless, these observations suggest a possible intracellu-
lar anabolic role of PEMF exposure. This eﬀect has also been
“indirectly” observed even for the tendon repair process. In a
preclinical animal model, Huegel et al. [8] showed a positive
result of PEMF exposure (for 1, 3, or 6 hours daily) in a rat
model of acute supraspinatus injury and repair, while Tucker
et al. [11] observed an improved early tendon healing follow-
ing PEMF exposure in a similar preclinical model of rotator
cuﬀ repair. The in vitro eﬀects of PEMF on tendon cells have
also been extensively examined, and several insights have
been clariﬁed. Indeed, PEMF may have a positive eﬀect
in promoting tenocyte gene expression and myoblast dif-
ferentiation as observed by Liu et al. [9]. These authors
demonstrated increased expression of growth factor genes
in a human rotator cuﬀ tenocytic cell line and an
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Figure 11: Comparison of IL-10 and VEGF expression between experimental and control groups. (a) Analysis of IL-10 levels in cultures
exposed to FGF-2 and PEMF (2 h/day) compared to cultures exposed only to FGF-2 and cultures without PEMF and FGF-2 exposures
after 7, 14, and 21 days. (b) Analysis of IL-10 levels in cultures exposed to FGF-2 and PEMF (4 h/day) compared to cultures exposed only
to FGF-2 and cultures without PEMF and FGF-2 exposures after 7, 14, and 21 days. (c) Analysis of IL-10 levels in cultures exposed to
FGF-2 and PEMF (8 h/day) compared to cultures exposed only to FGF-2 and cultures without PEMF and FGF-2 exposures after 7, 14,
and 21 days. (d) Analysis of VEGF levels in cultures exposed to FGF-2 and PEMF (2 h/day) compared to cultures exposed only to FGF-2
and cultures without PEMF and FGF-2 exposures after 7, 14, and 21 days. (e) Analysis of VEGF levels in cultures exposed to FGF-2 and
PEMF (4 h/day) compared to cultures exposed only to FGF-2 and cultures without PEMF and FGF-2 exposures after 7, 14, and 21 days.
(f) Analysis of VEGF levels in cultures exposed to FGF-2 and PEMF (8 h/day) compared to cultures exposed only to FGF-2 and cultures
without PEMF and FGF-2 exposures after 7, 14, and 21 days.
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increased myotube formation in a murine myoblast cell
culture. Previously, de Girolamo et al. [12, 13] had already
conﬁrmed a positive inﬂuence of PEMF scleraxis, type I
collagen, IL-6, IL-10, and VEGF expression in the human
tenocytic cell line derived. Thus, a positive role of PEMF
toward tendon commitment may be considered, summa-
rizing the eﬀect as (i) reduction of the catabolic eﬀects of
proinﬂammatory cytokines (such as IL-1) and (ii) promo-
tion of ECM production, anabolic cytokine release, and
cell proliferation through the increased expression of scler-
axis, VEGF, and COL1A1 genes and the release of IL-6,
IL-10, and TGF-β.
The present study is aimed at verifying the possible pos-
itive role of PEMF on a speciﬁc MSC source, namely, the
allogeneic human UC-MSCs. Indeed, the umbilical cord
eﬀectively represents a fascinating cell source and a hypothet-
ical therapeutic alternative for tendon and enthesis repair.
MSCs derived from the UC maintain a phenotype that reca-
pitulates some features with embryonic stem cells, having a
fetal origin, but without some crucial ethical concerns.
Indeed, UC is considered a discarded material, and it does
not involve any donor site morbidity. Thus, it represents a
good candidate for any “one-stage” procedures. Further-
more, it may be stored in any certiﬁed stem cell factory in
great amount, being available at demand, and thus it may
become an “oﬀ-the-shelf” cell population ready to be used
for diﬀerent reconstructive orthopaedic procedures [15, 16].
For all these reasons, UC-MSCs may represent an appealing
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Figure 12: Evaluation of cell mortality in UC-MSC cultures exposed to PEMF. (a) FACS analysis of annexin V/propidium iodide in cultures
exposed to FGF-2 and PEMF (2 h/day) after 7 days. (b) FACS analysis of annexin V/propidium iodide in cultures exposed to FGF-2 and
PEMF (4 h/day) after 7 days. (c) FACS analysis of annexin V/propidium iodide in cultures exposed to FGF-2 and PEMF (8 h/day) after 7
days. (d) FACS analysis of annexin V/propidium iodide in cultures exposed to FGF-2 and PEMF (2 h/day) after 14 days. (e) FACS
analysis of annexin V/propidium iodide in cultures exposed to FGF-2 and PEMF (4 h/day) after 14 days. (f) FACS analysis of annexin
V/propidium iodide in cultures exposed to FGF-2 and PEMF (8 h/day) after 14 days. (g) FACS analysis of annexin V/propidium iodide
in cultures exposed to FGF-2 and PEMF (2 h/day) after 21 days. (h) FACS analysis of annexin V/propidium iodide in cultures exposed
to FGF-2 and PEMF (4 h/day) after 21 days. (i) FACS analysis of annexin V/propidium iodide in cultures exposed to FGF-2 and PEMF
(8 h/day) after 21 days.
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alternative as a cell source for tendon healing in a hypo-
thetical preclinical and clinical setting. A further “collateral
suggestion” of the positive role of umbilical cord-derived
cells came recently from the preclinical xenogenic study
of Park et al. who showed the partial healing of a full-
thickness subscapularis tendon tear in rabbits by a simple
injection of human umbilical cord blood- (UCB-) derived
mesenchymal stem cells.
In our in vitro model, we observed a positive inﬂuence of
PEMF on the tenogenic diﬀerentiation of UC-MSC cultures.
Indeed, scleraxis and type I collagen expression was signiﬁ-
cantly increased following PEMF exposure. We also identi-
ﬁed the optimal time interval to increase tendon marker
expression and anabolic cytokine release. Indeed, we applied
diﬀerent time exposures to the UC-MSC cultures. Albeit all
types of exposures led to positive results, a greater diﬀerence
was observed in the PEMF3 group, compared to control
groups. Thus, these results suggest the 8-hour exposure as
the best PEMF exposure to stimulate UC-MSC tenogenic
potential. This result may also have a clinical relevance in
the perspective of the use of PEMF for improving the imme-
diate postoperative healing of tendon repairs.
We also observed reduced PCNA expression at the lon-
gest experimental time point. This result is consistent with
a predictable reduction in cell proliferation at day 21, due
to the presence of multiple diﬀerentiation stimuli in the cul-
ture setting, where the combined actions of PEMF, FGF-2,
and the soluble cytokines released by the UC-MSCs take
place. This observation seems to be in apparent contrast with
the previously described anabolic eﬀect of PEMF on mesen-
chymal cell lines. However, these data prove that a tenogenic
commitment at the end of the PEMF exposure physiologi-
cally leads to a decrease in cell proliferation. Moreover,
reduced PCNA expression was not observed at the early time
points (i.e., at days 7 and 14) of the culture exposed to PEMF
(8 h/day), suggesting that the exposure to PEMF might not
impair the very early healing phase of the tendon repair pro-
cess, when a proliferative state of the cell is desirable.
In our study, an increased release of IL-10 and VEGF was
detected at any time point during PEMF exposure, albeit the
increase was more signiﬁcant at day 21 and after 8 hours of
exposure. This observation emphasizes the possible teno-
genic role of PEMF exposure. Indeed, the eﬀect of the PEMF
seems to induce both a direct cellular commitment, as shown
by the increased expression of scleraxis and type I collagen,
and a concomitant indirect tenogenic activation by promot-
ing the release of soluble immunoregulatory cytokines such
as IL-10 and growth factors such as VEGF involved in ten-
don healing. The pattern of IL-10 and VEGF release paral-
lels the tenogenic marker expression, further conﬁrming the
exposure of 8 h/day as the better “anabolic protocol” for the
UC-MSCs.
Thus, the clinical relevance of our results may be hypoth-
esized. Firstly, our research conﬁrms the positive eﬀect of
PEMF on MSC tenogenic commitment. This perception
may suggest a broader application of this technique after
common reconstructive orthopaedic procedures as well as
rotator cuﬀ reconstruction. Indeed, during the early postop-
erative period, it is presumable that PEMF may exert both
an anti-inﬂammatory and anabolic eﬀect at the surgical site,
by interacting with the endogenous tissue-speciﬁc resident
MSCs, as suggested by Viganò et al. [25]. Evidence has also
been recently shown by Huegel et al. [8] in a preclinical
study of acute rotator cuﬀ injury. These authors showed pos-
itive eﬀects of PEMF on the repair site after transosseous
suture of acute supraspinatus transection in rats, observing
an increase in physical and histological properties of the
newly formed tissue. Similar results have been obtained by
Tucker et al. in a preclinical rat rotator cuﬀ repair model,
where an improved tendon healing was noticed at the early
phase of the repair [11]. Further large-scale clinical studies
may allow for conﬁrming these results with hopefully prom-
ising clinical results.
Secondly, a possible therapeutic strategy may be envi-
sioned combining the direct addition of allogeneic UC-
MSCs at the tendon repair site (i.e., the rotator cuﬀ insertion)
followed by an immediate postoperative PEMF treatment.
This solution may represent a possible alternative to improve
tendon repair by cell therapy, overcoming the unsuccessful
paradigm of uncommitted undiﬀerentiated MSC addition.
Indeed, the presence of biophysical stimuli driven by PEMF
may lead the UC-MSCs to a tenogenic commitment, realiz-
ing the concept of “MSC preconditioning” by a ﬁne tuning
of the cell microenvironment. Furthermore, UC-MSC teno-
genic activation by PEMF is much more economically sus-
tainable than the gene transfection described by Gulotta
et al. [7, 20].
Lastly, a diﬀerent therapeutic paradigm may be further
hypothesized, conceiving MSCs as a “biological factory” to
be used strictly in an in vitro condition. In this setting, a
“tenogenic” secretome may be obtained following UC-MSC
exposure to PEMF. This hypothetical “tenogenic secretome”
could be extracted and subsequently administered locally at
the surgical repair site at diﬀerent time points, exerting a pos-
itive eﬀect on tendon repair. This theory may actually repre-
sent an innovative perspective that would eliminate the
concerns on MSC delivery, and it would introduce the new
horizon of the “paracrine therapy” by means of PEMF-
exposed UC-MSCs. In the presence of local stem cell fac-
tories, a broader application of this concept may be envi-
sioned as an oﬀ-the-shelf cell-free one-step therapy for
tendon regeneration. The potential of this hypothesis has
recently been suggested by Sevivas et al. in preclinical models
of rat rotator cuﬀ tears [26, 27]. These authors observed a
decreased fatty degeneration and an increased muscular mass
improved after local injection of humanMSC secretome [26].
The authors also noticed an anabolic eﬀect of MSC secretome
on human tendon cells in vitro and an improvement in
enthesis reconstruction after implantation of the scaﬀolds
seeded with human tendon cells pretreated with human
MSC secretome [27]. An imperative attention to this new
approach involving MSC microvesicles is needed as it may
represent one of the ultimate evolutions of the use of stem
cells for tissue engineering [28].
However, our study has several limitations. First of all, it
suggests a therapeutic protocol based on in vitro observa-
tions. Indeed, the in vivomicroenvironment at the lesion site
and the presence of the natural inﬂammatory reaction may
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cause possible variations with regard to the positive eﬀects of
PEMF described in the present work. Albeit several observa-
tions in literature are in line with our results [8, 11, 25], the
promising eﬀect and the eﬃcacy of the association of PEMF
and UC-MSCs need to be further clariﬁed in preclinical
studies before any hypothetical clinical applications. Fur-
thermore, UC-MSC culture was performed in a monolayer
setting while, during any in vivo conceivable use of the “stem
cell therapy,” a scaﬀold is needed to host the cells and to
maintain the cells at the lesion site. Thus, a conﬁrmation
of the PEMF eﬀect on UC-MSCs in a tridimensional setting
may be desired before a direct preclinical application.
5. Conclusion
In this in vitro study, we observed that the PEMF exposure
generates a biophysical preconditioning eﬀect on UC-MSCs,
promoting the expression of tenogenic markers and anabolic
cytokines involved in tendon regeneration. Thus, PEMF
eﬀectively represents a potential key factor to promote MSC
tenogenic commitment.
This eﬀect is greater when a prolonged exposure of 8
hours per day is carried out. The positive results are more
pronounced at 21 days, suggesting a PEMF time-dependent
action on the UC-MSC tenogenic pathway.
Conﬁrming the anabolic properties of PEMF on MSC
tenogenic commitment, our study may have a clinical rele-
vance. Indeed, the newly described tenogenic eﬀects, along
with the well-known PEMF chondrogenic properties, suggest
a possible large-scale clinical application of this technique as
an adjuvant device in the early postoperative period of ten-
don surgical repair. Furthermore, the combined use of PEMF
and allogeneic UC-MSCs may be hypothesized as a future
therapeutic perspective for tendon tissue engineering, both
by a direct in situ cell delivery or by injection of the secretome
derived from PEMF-preconditioned UC-MSCs, to improve
tendon regeneration and enthesis restoration.
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